RE: no underlying reason for buyingI think what is promising about the company is the fact that they have a lot of resources (potential and tangible) to invest because they have almost no long-term liabilities. Also, their results haven't been completely speculative. It's phase II clinical testing of TNFerade for Esophagael Cancer is going really well, and they have presented 'encouraging data' at the American Society for Gene Therapy. Phase II showed that patients on this treatment had a median survival rate of just over four years, where comparable studies showed median survivals of 9-18 months. I think GenVec does have a lot of potential, granted it is speculative (as phase III is arguably the hardest hump for new treatments to get over) but I think it is a stock to keep an eye on at the very least.